1. Introduction {#sec1}
===============

Positron emission tomography (PET) and single photon emission computerised tomography (SPECT) imaging studies are frequently conducted in order to non-invasively investigate regulation of dopamine D~2/3~ receptors (D~2/3~) in healthy and diseased populations ([@bib1] [@bib52]). As such, D~2/3~ receptor PET and SPECT studies have contributed vastly to our understanding of dopaminergic neurotransmission in stimulant misuse and schizophrenia ([@bib27; @bib1; @bib52; @bib34]). A variety of D~2/3~ radioligands are sensitive to acute fluctuations in dopamine levels *in vivo* ([@bib28]), where the Occupancy Model is generally used to interpret the changes in binding observed. However, temporal discrepancies between the dopamine surge following treatment with compounds such as amphetamine and the change in D~2/3~ PET signal have been identified ([@bib30; @bib6; @bib23; @bib36; @bib45]). Furthermore, translation of endogenous release paradigms based on The Occupancy Model to other neurotransmitter systems have been relatively unsuccessful, suggesting that direct competition of radioligand by endogenous neurotransmitter molecule might not sufficiently describe the data.

Agonist-induced internalisation is a cellular mechanism which regulates secondary messenger signalling and functional receptor density at the plasma membrane ([@bib51]). Typically, following receptor activation and phosphorylation of intracellular domains by G-protein receptor kinases (GRK), the receptor-ligand complex is trafficked towards the endocytic machinery either for lysosomal degradation or to be prepared for re-insertion into the cell membrane. During this trafficking the receptor-ligand complex is exposed to a variety of ionic conditions, depending on its stage in the internalisation pathway. Compared with the D~1~ receptor ([@bib14; @bib33; @bib25]), D~2/3~ receptor internalisation is less extensively characterised. However D~2/3~ receptors have been shown to be present in the microsomal and cytosolic compartments in the absence of pharmacological stimulation using immunological based techniques ([@bib39]) and a few groups have demonstrated agonist-induced internalisation of the D~2~ receptor in cell and tissue preparations ([@bib24; @bib31; @bib39]). D~3~ receptor internalisation has also been observed following dopamine stimulation in cell systems ([@bib24; @bib7]).

An agonist-induced receptor internalisation model has been proposed to contribute to the signal changes observed in endogenous competition PET studies, known as the Internalisation Hypothesis ([@bib28]). Changes in receptor availability or affinity for a radioligand following internalisation may alter observed Binding Potential (BP); since BP is proportional to B~*max*~/K~*D*~. Following this proposal by [@bib28], a number of reports have been made in support of this Internalisation Hypothesis. Of note, [@bib45] used an internalisation deficient mouse model, and demonstrated the binding profiles of both \[^11^C\]MNPA and \[^18^F\]fallypride better matched the time course of dopamine release following amphetamine in the absence of internalisation ([@bib45]). Additionally, [@bib20] have shown the affinity of various D~2/3~ ligands to be altered following quinpirole-induced internalisation in cell systems ([@bib20]). More recently we have reported the ability of the selective serotonin transporter protein (SERT) radioligand, \[^3^H\]DASB, to bind to the SERT to be significantly reduced in sub-cellular conditions compared with membrane bound conditions utilising an *in vitro* model ([@bib41]).

The effect of changing sodium concentration and pH on dopamine receptor radioligand binding has been previously reported ([@bib21; @bib44; @bib54; @bib37; @bib47; @bib32]). However, to our knowledge, the effects of other ions which also differ throughout the agonist-mediated internalisation pathway, on the binding parameters of widely used PET radioligands, have not been investigated as extensively.

In general, the signal associated with any central nervous system PET radioligand is assumed to originate mainly from membrane bound target proteins. However, the contribution to the overall PET signal via the protein target of interest in sub-cellular compartments have not been reported with D~2/3~ receptor PET radioligands. Therefore, any involvement of the target protein in these sub-cellular compartments to the overall observed total PET signal will greatly increase our understanding of the cellular mechanisms involved in endogenous release studies for particular radioligands.

The data presented in this manuscript therefore sought to determine (1) how the agonist induced internalisation pathway may affect the binding parameters of the D~2/3~ radioligands, \[^3^H\]raclopride, \[^3^H\]PhNO and \[^3^H\]spiperone in tissue preparations using *in vitro* methods previously published for other PET radioligands ([@bib41]), and (2) the full cellular composition of the striatal PET signal for the D~2/3~ radioligands, spiperone, PhNO and raclopride at baseline using an *in vitro* cell fractionation system.

2. Methods {#sec2}
==========

2.1. Membrane preparation {#sec2.1}
-------------------------

### 2.1.1. Rat tissue {#sec2.1.1}

Male Sprague Dawley rats (∼250 g) were used for dissection and isolation of striatal tissue. Wet tissue was weighed and homogenised in 10× weight/volume (w/v) Sucrose buffer (0.32 mM Sucrose, 5 mM Tris HCl, 1 mM MgCl~2~ pH 7.4, 4 °C) and centrifuged at 32,000 *g* (20 min, 4 °C). The supernatant was removed and the pellet washed twice by centrifugation (32,000 *g*, 20 min, 4 °C) in Tris buffer (50 mM Tris-Base, 1 mM MgCl~2~, pH7.4, 4 °C). The final pellets were re-suspended in Tris buffer to approximately 10 mg/ml.

### 2.1.2. Sub-cellular fractionation {#sec2.1.2}

The sub-cellular fractionation procedure was based on methods previously presented ([@bib26; @bib50]). The constituents of the isolated fractions are: P1 = nuclear and cell debris fraction. P2 = plasma membrane and mitochondrial pellet. P3 = microsomal pellet diluted in endosomal buffer and S3 = cytosolic fraction.

The translation from rat to pig tissue was made based on data presented in [Supplementary Table 1, Supplementary Fig. 1](#appsec1){ref-type="sec"}. Rat and pig D~2/3~ radioligand receptor binding parameters were shown to be altered in a similar manor following exposure to the different cellular environments investigated in this manuscript i.e. lower *in vitro* BP values in the endosomal environment compared with the extracellular, driven by reductions in affinity. Furthermore, use of pig striatum allowed for reductions in animals numbers.

Striatal tissue (3 g) was isolated from each individual Danish Yorkshire Landrace pig (*n* = 3). Tissues were suspended in 10× w/v sucrose buffer and homogenised using a teflon glass homogeniser (20 strokes, on ice). The crude homogenate was centrifuged at a low speed (1000 *g*, 10 min, 4 °C) to generate the P1. The supernatant (S1) was set aside for further centrifugation. P1 was re-suspended in Tris buffer and washed twice by centrifugation at (1000 *g*, 10 min, 4 °C), with the resulting additional S1 supernatants added to the original supernatant (S1). The total S1 was centrifuged at a higher speed (17,000 *g*, 20 min, 4 °C) to generate P2. The supernatant resulting from this spin (S2) was set aside for further centrifugation. P2 pellet was re-suspended in Tris buffer and washed twice by centrifugation (32,000 *g*, 20 min, 4 °C), with the resulting additional S2 supernatants added to the original supernatant (S2). The total S2 was centrifuged (100,000 *g*, 90 min, 4 °C) to generate the P3. The supernatant from P3, S3, was collected as the cytosolic fraction of the striatal cells. P2 was resuspended in Extracellular buffer (see below). P3 was resuspended in endosomal buffer (see below). Samples of the cell fractions (250 μl of each) were assessed for protein content and the remainder aliquoted and stored at −80 °C for use in subsequent radioligand binding studies.

2.2. Radioligand Binding assays {#sec2.2}
-------------------------------

### 2.2.1. Saturation studies {#sec2.2.1}

Tissue samples (P2) generated from rat striatal membranes were diluted to 200 μg membrane protein/well in each of the three relevant physiological buffers, previously reported by [@bib41] (1) Extracellular (Extra = 50 mM Tris HCl, 140 mM NaCl, 5 mM KCl, 1.5 mM MgCl~2~, 1.5 mM CaCl~2~, pH 7.4, 37 °C); (2) Intracellular (Intra = 50 mM Tris HCl, 10 mM NaCl, 140 mM KCl, 0.5 mM MgCl~2~, pH 7.0, 37 °C) and (3) Endosomal (Endo = 20 mM MES, 10 mM NaCl, 140 mM KCl, 0.5 mM MgCl~2~, 0.003 mM CaCl~2~, pH 6.0, 37 °C) ([@bib41]); concentrations are adapted from [@bib5; @bib35; @bib18; @bib17; @bib19; @bib3; @bib8; @bib15; @bib48] and incubated (37 °C) with a range of radioligand concentrations (\[^3^H\]raclopride 0.003--30 nM, \[^3^H\]PhNO 0.003--10 and \[^3^H\]spiperone 0.003--10 nM). The specific binding component was determined using haloperidol (1 μM). Assays were terminated via filtration through Whatman GF/B filters followed by 4 × 1 ml washes with ice-cold Wash buffer (50 mM Tris HCl, pH 7.4, 4 °C). Filters were transferred to scintillation vials and scintillation fluid (3 ml/vial; Packard Ultima Gold MV) added and bound radioactivity determined on a Packard Tricarb liquid scintillation counter. Whatman GF/B filters were pre-incubated in polyethylenimine (PEI; 0.05%, 60 min) prior to filtration.

### 2.2.2. Sub-cellular fraction studies {#sec2.2.2}

Radioligand binding studies were performed from three independent fractionation procedures using pig striata. Fractions, P2, P3endo and S3, were diluted to 200 μg protein/well for addition to assay. These studies were performed using fixed concentrations of \[^3^H\]spiperone (5 nM), \[^3^H\]raclopride (20 nM) and \[^3^H\]PhNO (5 nM). The specific binding component was determined using haloperidol (1 μM). Following radioligand addition, assays were incubated at 37 °C (60 min). Assays were terminated via filtration and radioactivity counted as described above.

### 2.2.3. Kinetic studies {#sec2.2.3}

Rat striatal P2 homogenates were thawed and diluted to the desired concentration (200 μg membrane protein/well) in both extracellular and endosomal buffers. For association experiments, \[^3^H\]spiperone (1 nM), \[^3^H\]raclopride (2 nM) or \[^3^H\]PhNO (1 nM) were added at 22 time points between 0 and 100 min to wells containing 400 μl protein and 50 μl assay buffer. For dissociation studies, protein and \[^3^H\]spiperone (1 nM), \[^3^H\]raclopride (2 nM) or \[^3^H\](+)PhNO (1 nM) were added to the assay plate and allowed to associate at 37 °C for 100 min. Following this, haloperidol (1 μM) was added to the plate at 22 time points between 101 and 200 min, post-association in order to begin the dissociation. All time points were terminated simultaneously via filtration and radioactivity counted as described above.

2.3. Protein assay {#sec2.3}
------------------

Protein concentrations were determined by the colorimetric method using bicinchoninic acid assay at 562 nm (Thermo Scientific Pierce BCA Protein Assay Kit) ([@bib46]).

2.4. Data analysis {#sec2.4}
------------------

All data were analysed using GraphPad Prism 5.0. One- and Two-way ANOVA were performed using SigmaStat 3.0. Student\'s *t*-tests were performed using GraphPad Prism 5.0. B~*max*~ values in pmol/g tissue (nM) were generated according to Equation [(1)](#fd1){ref-type="disp-formula"} (where it is assumed that 1 ml of homogenised wet weight tissue is equivalent to 1 g in weight). *In vitro* binding potentials (BP) were generated using Equation [(2)](#fd2){ref-type="disp-formula"}. Relative Specific Activity (RSA) values were generated using Equation [(3)](#fd3){ref-type="disp-formula"} ([@bib26]). Kinetic parameters, k~on~ and K~*D*~ values were determined using Equations [(4) and (5)](#fd4 fd5){ref-type="disp-formula"}, respectively.

B~*max*~ in pmol/g tissue determination (where pmol/g is equivalent to nM);$$\text{B}_{max}^{'} = \frac{\text{B}_{max} \times \text{Protein}\ \text{content}}{\text{Mass}\ \text{tissue}}$$Where $\text{B}_{max}^{'}$ is the maximum number of binding sites expressed in pmol/g tissue equivalent to nM; B~*max*~ is the maximum number of binding sites expressed in fmol/mg of protein; "Mass tissue" in assay in g/ml; and "Protein content" in mg/ml and it is assumed that 1 g protein is the equivalent to 1 ml.

*In vitro* BP determination; $$iv\text{BP} = \frac{\text{B}_{max}^{'}}{K_{d}}$$Where *iv*BP is the *in vitro* binding potential (unit less); $\text{B}_{max}^{'}$ is the maximum number of binding sites expressed in pmol/g tissue equivalent to nM and *K*~*d*~ is the equilibrium dissociation constant in nM.

Relative specific activity (RSA) determination;$$\text{RSA} = \frac{\%\ \text{Specific}\ \text{binding}\ \text{per}\ \text{fraction}}{\%\ \text{Protein}\ \text{per}\ \text{fraction}}$$Where RSA is the relative specific activity in each fraction; "% Specific binding per fraction" is the percentage of total specific binding of the radioligand in the fraction and "% Protein per fraction" is the percentage of the total protein in the fraction.

k~*on*~ determination;$$k_{on} = \frac{\left( k_{obs} - k_{off} \right)}{\left\lbrack \text{radioligand} \right\rbrack}$$Where *k*~*on*~ is the rate constant of the association of radioligand and receptor in M^−1^ min^−1^; *k*~*obs*~ is the observed rate constant for the association of radioligand and receptor in min^−1^; *k*~*off*~ is the rate constant for the dissociation of radioligand and receptor in min^−1^ and \[radioligand\] is the concentration of radioligand in M.

Kinetic K~*D*~ determination;$$K_{d} = \frac{k_{off}}{k_{on}}$$Where *K*~*d*~ is the equilibrium dissociation constant in M; *k*~*off*~ is the rate constant for the dissociation of radioligand and receptor in min^−1^ and *k*~*on*~ is the rate constant of the association of radioligand and receptor in M^−1^ min^−1^.

3. Results {#sec3}
==========

3.1. Cellular environments {#sec3.1}
--------------------------

### 3.1.1. Saturation and kinetic studies -- \[^3^H\]raclopride and \[^3^H\]PhNO {#sec3.1.1}

For all K~*D*~ and B~*max*~ determinations plateaus were reached within the concentration ranges tested. The data from all conditions and radioligands tested were best fit to a single site. In general, changing the physiological environments had no effect on the observed B~*max*~ for either \[^3^H\]raclopride or \[^3^H\]PhNO ([Table 1](#tbl1){ref-type="table"}). A significant reduction in K~*D*~ for both \[^3^H\]PhNO and \[^3^H\]raclopride was observed in the endosomal condition compared with the extracellular condition ([Table 1](#tbl1){ref-type="table"}). Additionally, \[^3^H\]raclopride and \[^3^H\]PhNO kinetic K~*D*~ values obtained in the extracellular conditions were comparable with those obtained from saturation studies ([Table 2](#tbl2){ref-type="table"}). k~*off*~ rates for \[^3^H\]raclopride, and accurate k~*ob*~ values for \[^3^H\]PhNO were unable to be determined in the endosomal condition, with full inhibition of binding and association plateau not being achieved after 6 h following assay initiation ([Table 2](#tbl2){ref-type="table"}).

### 3.1.2. Saturation and kinetic studies -- \[^3^H\]spiperone {#sec3.1.2}

A significant effect of cellular environment was observed for K~*D*~ values obtained with \[^3^H\]spiperone ([Table 1](#tbl1){ref-type="table"}), however the magnitude of this change in K~*D*~ was less than that compared with \[^3^H\]raclopride or \[^3^H\]PhNO. The kinetic K~*D*~ obtained for \[^3^H\]spiperone was slightly lower (non-significant) than that determined from saturation studies ([Table 2](#tbl2){ref-type="table"}). In addition, the kinetic K~*D*~ determined in the extracellular condition was comparable to that in the endosomal condition. An increase in association rate was observed in the extracellular compared to the endosomal environment for \[^3^H\]spiperone; this was not significant ([Table 2](#tbl2){ref-type="table"}).

### 3.1.3. Saturation and kinetic studies -- *in vitro* BPs {#sec3.1.3}

*In vivo* PET data is generally reported in terms of binding potential (BP ∝ B~*max*~/K~*d*~). *In vitro* BPs were generated using Equation [(2)](#fd2){ref-type="disp-formula"} ([Table 1](#tbl1){ref-type="table"}). As expected from the saturation K~*D*~ values, a significant reduction in *in vitro* BP values were observed with \[^3^H\]raclopride, \[^3^H\]PhNO and \[^3^H\]spiperone in the endosomal environment compared to the extracellular ([Table 1](#tbl1){ref-type="table"}), therefore the following trend for the reduction in 'Percentage of Extracellular *in vitro* BP' in the endosomal condition was observed: \[^3^H\]PhNO \> \[^3^H\]raclopride \> \[^3^H\]spiperone ([Table 1](#tbl1){ref-type="table"}).

3.2. Sub-cellular fractionation {#sec3.2}
-------------------------------

The greatest amount of striatal cell protein was observed in the cytosolic fraction ([Table 3](#tbl3){ref-type="table"}). Lower levels were observed in the plasma membrane and microsomal fractions ([Table 3](#tbl3){ref-type="table"}).

For each of the three radioligands investigated, the majority of "Percent Bound per Fraction" was observed in the P2 fraction (∼67--83%) with lower levels bound to the P3 fraction (∼14--25%) and much lower levels bound to the S3 fraction (∼3--8%; [Table 3](#tbl3){ref-type="table"}). No significant differences in plasma membrane, microsomal or cytosolic percentage bound per fraction were observed when comparing the cellular distribution across the three radioligands ([Table 3](#tbl3){ref-type="table"}).

When both "Percentage Bound per Fraction" and "Percentage Total Protein per Fraction" are both taken into account i.e. using Equation [(3)](#fd3){ref-type="disp-formula"}, relative specific activity (RSA) values are generated. The total striatal homogenate RSA values for \[^3^H\]spiperone were found to be significantly greater than those obtained for both \[^3^H\]raclopride and \[^3^H\]PhNO ([Fig. 1](#fig1){ref-type="fig"}A, [Table 3](#tbl3){ref-type="table"}). Similar to the distribution of "Percentage total homogenate Bound per Fraction", RSA distribution was highest in the P2-plasma membrane fraction for all ligands ([Table 3](#tbl3){ref-type="table"}).

No significant differences were observed between \[^3^H\]raclopride, \[^3^H\]PhNO and \[^3^H\]spiperone P2 and S3 RSA values. However a significantly greater RSA value was present in P3 fractions with \[^3^H\]PhNO and \[^3^H\]spiperone when compared with \[^3^H\]raclopride ([Fig. 1](#fig1){ref-type="fig"}B, [Table 3](#tbl3){ref-type="table"}). A representation of striatal tissue fraction binding as a function of fraction protein content can be seen in [Fig. 1](#fig1){ref-type="fig"}C.

4. Discussion {#sec4}
=============

We have sought to determine the effects of three physiological environments reflective of the cellular compartments experienced by a receptor following agonist-induced internalisation, on the binding parameters of the D~2/3~ radioligands \[^3^H\]raclopride, \[^3^H\]PhNO and \[^3^H\]spiperone. The relative contribution of each of these three cellular compartments (extracellular, intracellular and endosomal) to the overall basal PET signal given by the PET ligands raclopride, PhNO and spiperone have also been estimated. Using *in vitro* radioligand binding, a reduction in affinity was observed for \[^3^H\]raclopride and \[^3^H\]PhNO in the endosomal compared with the extracellular environment; two radioligands with known sensitivity to endogenous release *in vivo*. Alterations in receptor kinetics in the different cell conditions may underpin these changes in affinity. Affinity shifts with changing cellular environment lead to a reduction in *in vitro* BP generated for these radioligands, the magnitude of which was related to the change in BP following endogenous dopamine release observed previously *in vivo* with these ligands. Notably, compared with \[^3^H\]raclopride and \[^3^H\]PhNO, a smaller change in affinity was observed in the endosomal condition compared with the extracellular condition for \[^3^H\]spiperone, a radioligand thought not to be sensitive to endogenous dopamine release *in vivo*. These data suggest that changes in receptor affinity following dopamine release and subsequent agonist-induced internalisation may contribute to reductions in BP observed *in vivo*, since BP is proportional to B~*max*~/K~*D*~. Using sub-cellular fractionation we estimated that in the absence of a pharmacological challenge, the majority (∼67--∼83%) of the total signal associated with \[^3^H\]raclopride, \[^3^H\]PhNO and \[^3^H\]spiperone would result from membrane bound D~2/3~ receptors. In agreement with our saturation data we also demonstrate that ∼25% of total striatal binding for \[^3^H\[spiperone originates from sub-cellular, microsomal receptors, whereas for \[^3^H\]raclopride and \[^3^H\]PhNO, this fraction is lower, representing ∼14% and 17%, respectively. The cytosolic fraction contributes negligibly to the overall PET signal.

4.1. Effect of physiological environments on the binding properties of \[^3^H\]raclopride, \[^3^H\]PhNO and \[^3^H\]spiperone {#sec4.1}
-----------------------------------------------------------------------------------------------------------------------------

Receptor availabilities (B~*max*~) and affinity (K~*D*~) values for all three radioligands were generated in the extracellular environment and found to be comparable to those previously reported in the literature ([@bib42; @bib10]). In order to recreate the cellular environments present at each of the sub-cellular and cell surface compartments as accurately as possible, a variety of literature sources were consulted that have examined the ionic compositions of various cell compartments and organelles ([@bib5; @bib35; @bib18; @bib17; @bib19; @bib3; @bib8; @bib15; @bib48]). These cellular buffers have previously been used to investigate the effects of serotonin transporter endocytosis and sub-cellular localisation on the binding of \[^3^H\]DASB ([@bib41]). To further validate the translation from the effects of the cellular buffers on surface receptors in an endosomal condition to endosomal receptors (found in the P3 fraction) we have performed P3 binding in both extracellular and endosomal conditions. With \[^3^H\]raclopride, for example, P3 binding is 1.98 fold higher in the extracellular condition (RSA = 1.77) compared with when conducted in the endosomal condition (RSA = 0.89). Interpolating from the saturation binding curves conducted in P2 homogenates in different cellular buffers at the radioligand concentration used in the fractionation binding studies (20 nM for \[^3^H\]raclopride), the specific binding in the extracellular condition is 1.95 fold greater in the extracellular condition (331.4 fmol/mg) compared with the endosomal condition (170.5 fmol/mgn). We consider these binding shifts very similar and therefore assume these are representative of the affinity shift experienced by endosomally trafficking receptors.

The effects of changing sodium levels on receptor affinity for benzamide ligands, e.g. raclopride, and butyrophenone ligands, e.g. spiperone have previously been investigated ([@bib49; @bib16; @bib37; @bib38; @bib11]). However, the effects of these changing ionic conditions have been less extensively investigated for the D~3~-preferring agonist ligand, \[^3^H\]PhNO. Additionally, the effect of changing the ionic composition of not just sodium but also pH, calcium, potassium, magnesium and chloride ions to concentrations representative of those found in the extracellular, intracellular and endosomal compartments on the specific binding of the three D~2/3~ ligands have also not been reported previously.

In agreement with the saturation data presented here, [@bib37] demonstrated a decrease in benzamide (\[^125^I\]epidepride), but not butyrophenone ligand (\[^3^H\]spiperone), affinity following a reduction in assay pH and sodium concentration. Two amino-acid sites within the D~2~ are thought to confer benzamide pH and sodium sensitivity with a pK~*a*~ of 6--7, whereas one site with a pK~*a*~ of 5.5--6.1 is thought to confer this sensitivity for butyrophenone ligands ([@bib11]). Within our physiological buffers, both amino-acids required for benzamide binding could be ionised at pH6.0 within the endosomal condition leading to the reduction in \[^3^H\]raclopride binding. This pH of 6.0 may not be acidic enough to cause the ionisation of the single site required for \[^3^H\]spiperone binding, which would account for \[^3^H\]spiperone appearing less sensitive to the different conditions tested in this study. \[^3^H\]PhNO was more sensitive to changes in ionic environment than the D~2/3~ receptor antagonist radioligands, suggesting that the endosomal environment may be less favourable for D~2~^high^ receptor than for D~2~^low^ receptor binding. Inclusion of magnesium and calcium ions in assay buffers has been shown to increase affinity of agonist ligands such as NPA and apomorphine ([@bib44; @bib2]). However, no significant reduction in affinity was observed from extracellular to intracellular (where magnesium and calcium were both depleted compared to the extracellular) but when, pH was further dropped from 7.0 to 6.0 (and magnesium and calcium were still depleted), \[^3^H\]PhNO affinity was significantly reduced. Therefore the dramatic loss of affinity observed by \[^3^H\]PhNO appears to be mainly pH driven. Together, these data further support the idea that agonist PET ligands may be preferential for use when trying to image endogenous release *in vivo* since they would be expected to exhibit a greater loss of receptor affinity and hence a greater decrease in *in vivo* BP following endogenous transmitter release and translocation to the endosomal compartment.

[@bib20] have demonstrated a similar affinity shift following quinpirole induced D~2~ receptor internalisation of raclopride, PhNO and spiperone in D~2short~ expressing cell systems. Building upon these findings, we suggest that following internalisation of D~2/3~ receptors to endosomal vesicles, the decrease in affinity observed may be driven by alterations in receptor binding kinetics. For both \[^3^H\]raclopride and \[^3^H\]PhNO, two ligands known to be sensitive to endogenous release of dopamine *in vivo*, we show incomplete equilibrium kinetics in the endosomal compartment compared with that observed at the plasma membrane. Furthermore, no significant changes in the kinetic parameters measured were observed between extracellular and endosomal cellular environments with \[^3^H\]spiperone. These data support, both homogenate binding studies and *in vivo* dosing data, which suggest \[^3^H\]spiperone binding is less sensitive to changes in sodium and hydrogen ion concentration and intracellular trapping of \[^3^H\]spiperone following endocytosis of D~2/3~ receptors ([@bib9]). Importantly, we report the change in *in vitro* BP from the extracellular to the endosomal condition is consistent with the known sensitivity to endogenous dopamine release previously observed *in vivo* i.e. \[^11^C/^3^H\]PhNO \> \[^11^C/^3^H\]raclopride \> \[^11^C/^3^H\]spiperone ([@bib22; @bib43]). These findings suggest that in addition to different pharmacological properties of radioligands (i.e. antagonist versus agonist radioligands) contributing to sensitivity to endogenous neurotransmitter release, a greater effect of receptor internalisation on radioligand binding parameters may also drive an increased vulnerability to signal changes observed *in vivo* with \[^11^C/^3^H\]PhNO compared with \[^11^C/^3^H\]raclopride or \[^11^C/^3^H\]spiperone. Investigating the sensitivity of other D~2/3~ radioligand\'s (such as NPA, fallypride and FLB 457), to the different environments used in our assays therefore now warrants further investigation.

4.2. Cellular composition of striatal binding for \[^3^H\]raclopride, \[^3^H\]PhNO and \[^3^H\]spiperone {#sec4.2}
--------------------------------------------------------------------------------------------------------

The cellular and sub-cellular distribution of dopamine receptors have previously been described ([@bib9; @bib55; @bib4; @bib50; @bib53]). We present relative specific activity values (RSA), which represent binding as a function of fraction protein content ([@bib26]). D~2~ expression has been observed previously in cytosolic fractions using semi-quantitative Western blot analysis ([@bib53]) and electron microscopy ([@bib39]). D~3~ receptor cytoplasmic and intracellular vesicle localisation has also been noted ([@bib12]). Together with the binding data from the cytosolic compartment (S3), this suggests that both D~2~ and D~3~ receptors may be present in the cytoplasm but may not be in the correct tertiary conformation necessary for radioligand binding, and hence contributes very little to total the tissue binding as a consequence. Despite the highest levels of binding emanating from the plasma membrane fractions for all three radioligands, the 'Percent Bound Per Fraction' obtained for P2 and P3 for \[^3^H\]raclopride, \[^3^H\](+)PhNO and \[^3^H\]spiperone suggests that a significant proportion of the signals observed *in vivo* could be due to subcellular, microsomal binding. The RSA values for both \[^3^H\]spiperone and \[^3^H\]PhNO in the microsomal fraction were greater than that observed for \[^3^H\]raclopride. This may represent an increased abundance of D~3~ receptor in the sub-cellular compartments which would lead to increases in \[^3^H\]PhNO binding in the microsomal compartments compared with \[^3^H\]raclopride. Increased \[^3^H\]spiperone binding in microsomal fractions maybe due to sequestered levels of 5HT~2A~ receptors. \[^3^H\]Spiperone has been shown to have significant affinity at 5HT~2A~ receptors (∼0.5 nM in transfected HEK293 cells) ([@bib40]). Furthermore, the majority 5HT~2A~ receptors located on dendrites of rat ventral tegmental area dopaminergic cells have been shown to be sub-cellularly located ([@bib13]).

In this manuscript we describe the cellular composition of total striatal tissue binding with \[^3^H\]raclopride, \[^3^H\]PhNO and \[^3^H\]spiperone. [@bib29] recently proposed an updated D~2~ receptor model with reference to D~2/3~ PET imaging, whereby ∼60% of striatal D~2/3~ are configured in a high affinity state and ∼35% are configured in a low affinity state (based on studies comparing agonist versus antagonist D~2/3~ PET ligands) ([@bib29]). We demonstrate here a population of receptors, similar in 'Percent Bound Per Fraction' across all three radioligands that represents D~2/3~ at the plasma membrane (∼67--∼83%). This population is comparable in magnitude to that described by [@bib29] when combining both D~2/3~^high/low^ but excluding a population of extrasynaptic or internalised D~2/3~ receptors (∼75% ([@bib29])). The studies presented here do not distinguish between synaptic and extrasynaptic D~2/3~, however we propose that despite the similarities in proportions of membrane bound receptors (comprising the majority of total striatal binding for all three radioligands tested) the differences in their behaviours following endogenous dopamine release *in vivo* will possibly be dependent on their ability to bind D~2/3~ following internalisation. This is reflected using both saturation studies conducted in different cellular environments and sub-cellular fractionation studies where for \[^3^H\]raclopride and \[^3^H\]PhNO, the microsomal fraction contribution to total striatal binding (∼14% and 17%, respectively) is considerably smaller compared with that of \[^3^H\]spiperone\'s (∼25%). Sub-cellular fractionation following pharmacological challenge remains to be conducted using the methodology implemented in this manuscript. However, we demonstrate using the percent bound per fraction for each radioligand and the affinity values for each ligand in each physiological buffer, the expected magnitude of signal change should a constant amount of membrane D~2/3~ endocytose to the microsomal compartment (20% internalisation is used an example, see [Table 4](#tbl4){ref-type="table"}). These data suggest that following endocytosis, the total striatal binding capacity for \[^3^H\]raclopride, \[^3^H\]PhNO and \[^3^H\]spiperone would be reduced in the same rank order as that seen *in vivo* with these ligands following administration of a dopamine releasing agent i.e. \[^3^H\]PhNO (17.2%) \> \[^3^H\]raclopride (14.5%) \> \[^3^H\]spiperone (11.5%). These data remain to be corroborated in a pharmacological challenge model using the methodology implemented here. We believe this would be of benefit to furthering our understanding of the cellular mechanisms underpinning signal changes observed *in vivo* not only with D~2/3~ receptors but, also other receptor radioligands sensitive to change following endogenous neurotransmitter release.

In summary, using *in vitro* radioligand binding studies, we have demonstrated that a reduction in affinity was observed for all ligands tested in the endosomal compared with the extracellular environment. The magnitude of this affinity shift with changing cellular environment was related to the change in BP reported previously *in vivo* with these ligands i.e. \[^3^H\]raclopride and \[^3^H\]PhNO displayed a much greater reduction in binding in the endosomal condition compared with \[^3^H\]spiperone, a radioligand thought not to be sensitive to endogenous dopamine release *in vivo*. Therefore, we suggest that assessment of these affinity shifts predicts ligand sensitivity to endogenous dopamine release. Using sub-cellular fractionation assays we have estimated that in the absence of a pharmacological challenge, the majority (∼67--∼83%) of the total signal associated with \[^3^H\]raclopride, \[^3^H\]PhNO and \[^3^H\]spiperone would result from membrane bound D~2/3~ receptors; with a significant (∼14--∼25%) contribution being derived from microsomal D~2/3~ receptors and the cytosolic fraction contributing negligibly to the overall PET signal.

This novel approach for estimating the cellular composition of a PET signal under basal conditions now warrants further use for other receptor PET ligands. Determination of susceptibility to affinity shifts following receptor internalisation may be a crucial radioligand characteristic for determining sensitivity to neurotransmitter release *in vivo*. As such, the data presented here may help translate *in vivo* competition imaging techniques to neurotransmitter systems outside the D~2/3~. Translational approaches such as this, allow for an enhanced understanding of the pharmacology underlying the *in vivo* PET signals for multiple receptor systems, from both endogenous transmitter release and exogenous challenge studies.
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The following are the supplementary data related to this article:

![**A.** Comparison of \[^3^H\]raclopride, \[^3^H\]PhNO and \[^3^H\]spiperone "Total Homogenate RSA values". Total homogenate binding observed following sub-cellular fractionation of pig striatal membranes; *n* = 3 for \[^3^H\]raclopride and \[^3^H\]PhNO; *n* = 2 for \[^3^H\]spiperone (mean ± s.e.mean). One-way ANOVA with Tukey post-test were performed using SigmaStat 3.0. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 represent comparison of \[^3^H\]spiperone RSA to both \[^3^H\]raclopride and \[^3^H\]PhNO. **B.** Microsomal fraction RSA values with \[^3^H\]raclopride, \[^3^H\]PhNO and \[^3^H\]spiperone. \[^3^H\]Raclopride and \[^3^H\]PhNO *n* = 3; *n* = 2 for \[^3^H\]spiperone (mean ± s.e.mean). ^∗^*p* \< 0.05 represent comparison of \[^3^H\]raclopride P3 RSA with \[^3^H\]spiperone and \[^3^H\]PhNO P3 RSA. **C.** Representation of homogenate binding as a function of cell protein. Relative specific activity (RSA) versus percent total protein per fraction histogram for \[^3^H\]raclopride, \[^3^H\](+)PhNO and \[^3^H\]spiperone from pig striatal sub-cellular fractionation; *n* = 3 for \[^3^H\]raclopride and \[^3^H\]PhNO; *n* = 2 for \[^3^H\]spiperone (mean ± s.e.mean).](gr1){#fig1}

###### 

K~*D*~, B~*max*~ and *in vitro* BP values for each radioligand in the three physiological environments.

  Radioligand and buffer   K~*D*~ (nM)   B~*max*~ (fmol/mg protein)   B~*max*~ (pmol/g tissue)   *In vitro* BP   \% of extra *in vitro* BP~p~   
  ------------------------ ------------- ---------------------------- -------------------------- --------------- ------------------------------ -----
  \[^3^H\]Raclopride                                                                                                                            
                           Extra         2.0 ± 0.2                    368 ± 80                   13.8 ± 0.8      6.9 ± 0.1                      100
                           Intra         4.3 ± 0.8                    381 ± 86                   12.9 ± 0.7      3.2 ± 0.3                      47
                           Endo          9.5 ± 3.6^∗∗^                292 ± 68                   9.1 ± 0.5       1.2 ± 0.3^∗∗^                  18
  \[^3^H\]PhNO                                                                                                                                  
                           Extra         0.6 ± 0.1                    130 ± 21                   7.2 ± 0.2       14.5 ± 4.1                     100
                           Intra         0.3 ± 0.1                    169 ± 32                   8.2 ± 0.5       25.4 ± 5.7                     174
                           Endo          10.3 ± 2.7^∗∗^               103 ± 41                   6.1 ± 1.6       0.6 ± 0.1^∗∗^                  4
  \[^3^H\]Spiperone                                                                                                                             
                           Extra         0.1 ± 0.01                   265 ± 39                   15.2 ± 0.5      179.5 ± 28.1                   100
                           Intra         0.1 ± 0.1                    349 ± 35                   18.6 ± 1.6      168.1 ± 10.9                   93
                           Endo          0.4 ± 0.2^∗^                 278 ± 51                   18.3 ± 1.9      68.43 ± 14.2^∗^                38

K~*D*~ (nM) and B~*max*~ (fmol/mg protein and pmol/g tissue) and *in vitro* BP values for \[^3^H\]raclopride, \[^3^H\](+)PhNO and \[^3^H\]spiperone in rat striatum (*n* = 4, mean ± s.e.mean) in the three ionic environments (Extra, Intra and Endo). One-way ANOVA with Tukey post-test were performed using SigmaStat 3.0. ^∗^*p \<* 0.05 and ^∗∗^*p \<* 0.01 represent comparison of intracellular or endosomal to the extracellular condition.

ANOVA results. \[^3^H\]Raclopride, K~*D*~: *F*(3,20) = 12.47, *p* \< 0.07; B~*max*~: *F*(2,20) = 3.40, *p* = 0.053. \[^3^H\]PhNO, K~*D*~: *F*(2,21) = 5.95, *p* \< 0.009; B~*max*~: *F*(2,20) = 1.30, *p* = 0.03. \[^3^H\]Spiperone, K~*D*~: *F*(2,22) = 3.28, *p* \< 0.057; B~*max*~: *F*(2,22) = 2.76, *p* \< 0.085.

###### 

Kinetic values for radioligands in extracellular and endosomal conditions.

  Radioligand and buffer   k~*off*~ (min^−1^)   k~*ob*~ (min^−1^)   k~*on*~ (M^−1^ min^−1^)   Kinetic K~*D*~ (nM)   Saturation K~D~ (nM)   Fold difference^\$^   
  ------------------------ -------------------- ------------------- ------------------------- --------------------- ---------------------- --------------------- ------------
  \[^3^H\]Raclopride                                                                                                                                             
                           Extra                0.4 ± 0.02          1.1 ± 0.2                 0.5 ± 0.3             1.1 ± 0.5              2.0 ± 0.2             1.8 ± 1.1
                           Endo                 ND                  0.03 ± 0.01               ND                    −/−                    9.5 ± 3.6             −/−
  \[^3^H\]PhNO                                                                                                                                                   
                           Extra                0.1 ± 0.02          0.6 ± 1.6                 0.4 ± 0.3             0.7 ± 0.1              0.6 ± 0.1             0.9 ± 0.1
                           Endo                 0.1 ± 0.1           ND                        ND                    −/−                    10.3 ± 2.7            −/−
  \[^3^H\]Spiperone                                                                                                                                              
                           Extra                0.1 ± 0.01          0.4 ± 0.2                 0.4 ± 0.2             0.6 ± 0.5              0.1 ± 0.01            0.2 ± 0.02
                           Endo                 0.1 ± 0.03          0.2 ± 0.02                0.1 ± 0.04            1.0 ± 0.5              0.4 ± 0.2             0.4 ± 0.4

k~*off*~ (min^−1^), k~*ob*~ (min^−1^), k~*on*~ (M^−1^ min^−1^), Kinetic K~*D*~ (nM) and Saturation K~*D*~ (nM)/Kinetic K~*D*~ (nM) fold difference for \[^3^H\]raclopride (*n* = 3 extra, *n* = 5 endo), \[^3^H\](+)PhNO (*n* = 4 extra, *n* = 2 endo) and \[^3^H\]spiperone (*n* = 3 extra, *n* = 3 endo; all data are mean ± s.e.mean). ^\$^Represent Saturation K~*D*~/Kinetic K~*D*~. All data analysed with GraphPad Prism 5.0 using single site exponential association and dissociation fits.

###### 

Sub-cellular fractionation data from pig striatal membranes.

  Radioligand and fraction   \% Total protein per fraction   \% Bound per fraction   Homogenate RSA   
  -------------------------- ------------------------------- ----------------------- ---------------- -------------------------
  \[^3^H\]Raclopride                                                                                  
                             P2                              28.9 ± 4.5              82.5 ± 7.4       2.0 ± 0.3
                             P3                              15.6 ± 1.3              14.3 ± 7.5       0.9 ± 0.5
                             S3                              55.5 ± 4.9              3.2 ± 1.8        0.1 ± 0.03
                                                                                                      *Total* = *3.0*^*\**^
  \[^3^H\]PhNO                                                                                        
                             P2                              28.9 ± 4.5              79.6 ± 2.5       2.1 ± 0.3
                             P3                              15.6 ± 1.3              17.3 ± 2.6       1.1 ± 0.1
                             S3                              55.5 ± 4.9              3.2 ± 1.7        0.1 ± 0.03
                                                                                                      *Total* = *3.3*^*\*\**^
  \[^3^H\]Spiperone                                                                                   
                             P2                              18.1 ± 1.3              67.2 ± 2.9       3.6 ± 0.1
                             P3                              16.1 ± 2.7              24.5 ± 7.2       1.5 ± 0.2
                             S3                              65.1 ± 4.0              8.3 ± 10.1       0.1 ± 0.2
                                                                                                      *Total* = *5.2*

Percentage of total amount protein per fraction, Percentage of total amount of \[^3^H\]raclopride \[^3^H\](+)PhNO and \[^3^H\]spiperone bound to each fraction (P2, P3 and S3), relative specific activity (RSA) and Percentage of total binding signal (where 100% = P2 + P3 + S3) for \[^3^H\]raclopride, \[^3^H\](+)PhNO and \[^3^H\]spiperone from pig striatal membrane fractionation studies (*n* = 3, mean ± s.e.mean). ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 represent comparison of total homogenate RSA. Total homogenate RSA. \[^3^H\]Raclopride and \[^3^H\[PhNO binding were performed on the same striatal homogenate fractionation preparations, \[^3^H\]spiperone binding was performed on a separate set of striatal preparations.

ANOVA results *F*(2,5) = 13.49, *p* = 0.0097. P3 RSA ANOVA results: *F*(2,4) = 13.55, *p* = 0.017.

###### 

Prediction of alteration in total binding following D~2/3~ endocytosis.

  Radioligand          K~*D*~ (nM)   \% Bound per fraction   Fraction binding capacity (% binding per fraction/K~*D*~)   20% of surface receptors endocytose -- % binding/fraction^€^   Fraction binding capacity post-endocytosis (% binding per fraction/K~*D*~)
  -------------------- ------------- ----------------------- ----------------------------------------------------------- -------------------------------------------------------------- ----------------------------------------------------------------------------
  \[^3^H\]Raclopride                                                                                                                                                                    
  Cell Surface         2.0 (extra)   82.5 (P2)               41.3                                                        66.0                                                           33.0
  Microsomal           9.5 (endo)    14.3 (P3)               1.5                                                         32.8                                                           3.5
  Cytosol              4.3 (intra)   3.2 (S3)                0.7                                                         3.2                                                            0.7
                                                             *Total: 43.5*                                                                                                              *Total: 37.2****(14.5% reduction)***
  \[^3^H\]PhNO                                                                                                                                                                          
  Cell Surface         0.6 (extra)   79.6 (P2)               132.7                                                       63.7                                                           106.2
  Microsomal           10.3 (endo)   17.3 (P3)               1.68                                                        33.2                                                           3.3
  Cytosol              0.3 (intra)   3.2 (S3)                10.7                                                        10.7                                                           10.7
                                                             *Total: 145.0*                                                                                                             *Total: 120****(17.2% reduction)***
  \[^3^H\]Spiperone                                                                                                                                                                     
  Cell Surface         0.1 (extra)   67.2 (P2)               672.1                                                       53.8                                                           538
  Microsomal           0.4 (endo)    24.5 (P3)               81.7                                                        37.0                                                           126.3
  Cytosol              0.1 (intra)   8.3 (S3)                21.5                                                        8.3                                                            21.5
                                                             *Total: 775.2*                                                                                                             *Total: 685****(11.5% reduction)***

Prediction of alteration in total binding following D~2/3~ endocytosis. ^€^Assumes that 20% of surface, membrane bound receptors endocytose to the microsomal compartment, and that no lysosomal trafficking and degradation of existing receptors occurs.
